Akebia Therapeutics Inc. buy BTIG Research
Start price
02.12.25
/
50%
€1.27
Target price
02.12.26
€4.31
Performance (%)
-3.45%
Price
17.07.26
?
Summary
This prediction is currently active. With a performance of -3.45%, the BUY prediction by BTIG_Research is trending in the wrong direction. This prediction currently runs until 02.12.26. The prediction end date can be changed by BTIG_Research at any time. BTIG_Research has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akebia Therapeutics Inc. | -2.428% | -2.428% |
| iShares Core DAX® | -1,09 % | 0,20 % |
| iShares Nasdaq 100 | -2,46 % | -1,79 % |
| iShares Nikkei 225® | -5,37 % | -5,43 % |
| iShares S&P 500 | -0,20 % | 1,77 % |
Comments by BTIG_Research for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Stopped prediction by BTIG_Research for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.18
07.04.26
07.04.26
€3.47
07.04.27
07.04.27
0.81%
17.07.26
17.07.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.08
25.02.26
25.02.26
€3.39
25.02.27
25.02.27
14.31%
17.07.26
17.07.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.93
29.10.25
29.10.25
€4.29
29.10.26
29.10.26
-36.20%
17.07.26
17.07.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.92
29.11.23
29.11.23
€3.64
29.11.24
29.11.24
122.78%
30.11.24
30.11.24